Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen clinical trials

A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.

This study looks at how well a medicine called Kesimpta works for people with a type of multiple sclerosis called relapsing multiple sclerosis (RMS). It also checks for side effects and how people feel on the treatment, especially those switching from other MS medicines.